Targeted immunotherapy of high‑grade cervical intra‑epithelial neoplasia: Expectations from clinical trials (Review)

  • Authors:
    • Jean‑Luc Brun
    • José Rajaonarison
    • Nicolas Nocart
    • Laura Hoarau
    • Stéphanie Brun
    • Isabelle Garrigue
  • View Affiliations

  • Published online on: December 8, 2017     https://doi.org/10.3892/mco.2017.1531
  • Pages: 227-235
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Targeted immunotherapy of high‑grade cervical intra-epithelial neoplasia (CIN) has been developed as an alternative to conization, to preserve future reproductive outcomes and avoid human papillomavirus (HPV) persistence. The objectives of the review are to present drugs according to their process of development and to examine their potential future use. A search for key words associated with CIN and targeted immunotherapy was carried out in the Cochrane library, Pubmed, Embase, and ClinicalTrials.gov from 1990 to 2016. Publications (randomized, prospective and retrospective studies) in any language were eligible for inclusion, as well as ongoing trials registered on the ClinicalTrials.gov website. Targeted immunotherapy includes peptide/protein‑based vaccines, nucleic acid‑based vaccines (DNA), and live vector‑based vaccines (bacterial or viral). A total of 18 vaccines were identified for treatment of CIN at various stages of development, and the majority were well‑tolerated. Adverse effects were primarily injection site reactions and flu‑like symptoms under grade 2. The efficacy of vaccines defined by regression of CIN2/3 to no CIN or CIN1 ranged from 17 to 59% following a minimum of a 12‑week follow‑up. In the majority of studies, there was no association demonstrated between histological response and HPV clearance, or between histological or virological response and immune T cell response. Given that the spontaneous regression of CIN2/3 is 20‑25% at 6 months, targeted immunotherapy occurs an additional value, which never reaches 50%, with one trial an exception to this. However, research and development on HPV eradication drugs needs to be encouraged, due to HPV‑associated disease burden.

Related Articles

Journal Cover

February 2018
Volume 8 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Brun, J., Rajaonarison, J., Nocart, N., Hoarau, L., Brun, S., & Garrigue, I. (2018). Targeted immunotherapy of high‑grade cervical intra‑epithelial neoplasia: Expectations from clinical trials (Review). Molecular and Clinical Oncology, 8, 227-235. https://doi.org/10.3892/mco.2017.1531
MLA
Brun, J., Rajaonarison, J., Nocart, N., Hoarau, L., Brun, S., Garrigue, I."Targeted immunotherapy of high‑grade cervical intra‑epithelial neoplasia: Expectations from clinical trials (Review)". Molecular and Clinical Oncology 8.2 (2018): 227-235.
Chicago
Brun, J., Rajaonarison, J., Nocart, N., Hoarau, L., Brun, S., Garrigue, I."Targeted immunotherapy of high‑grade cervical intra‑epithelial neoplasia: Expectations from clinical trials (Review)". Molecular and Clinical Oncology 8, no. 2 (2018): 227-235. https://doi.org/10.3892/mco.2017.1531